Daewoong Pharmaceutical Acquires Turn Biotechnologies’ Core Age-Reversal Technology Assets

Daewoong Pharmaceutical reported on May 21, 2026, that it acquired core technology assets and rights from Turn Biotechnologies through an auction bid and plans to pursue treatments for aging-related diseases. On this page you can read the full post, open the connected company profile, view related posts, check likes and publication details.